Cerence Inc. (BMV:CRNC)
Mexico · Delayed Price · Currency is MXN 157.00
0.00 (0.00%)
At close: Jul 31, 2025, 2:00 PM CST
CTI BioPharma Cash Flow Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2018 - 2020 |
Net Income | -25.77 | -588.08 | -56.25 | -310.83 | 45.89 | -18.32 | Upgrade |
Depreciation & Amortization | 8.39 | 7.93 | 12.04 | 20.24 | 26.26 | 26.94 | Upgrade |
Other Amortization | 2.7 | 2.7 | 4 | 3.7 | 3.4 | 3.1 | Upgrade |
Asset Writedown & Restructuring Costs | - | 609.17 | - | 213.72 | - | - | Upgrade |
Stock-Based Compensation | 24.43 | 23.67 | 40.77 | 28.08 | 60.56 | 47.29 | Upgrade |
Provision & Write-off of Bad Debts | 0.13 | 3.55 | 3.63 | -0.41 | -0.42 | 0.7 | Upgrade |
Other Operating Activities | -5.92 | -0.12 | 5.06 | 108.68 | -0.01 | 14 | Upgrade |
Change in Accounts Receivable | 12.57 | 11.76 | -16.96 | -6.59 | 5.75 | 15.15 | Upgrade |
Change in Accounts Payable | -4.84 | -12.56 | 5.77 | 0.16 | 3.41 | -2.43 | Upgrade |
Change in Unearned Revenue | 26.72 | -61.04 | -21.53 | -28.3 | -45.65 | -35.99 | Upgrade |
Change in Other Net Operating Assets | 16.12 | 20.21 | 30.98 | -30.58 | -24.8 | -5.65 | Upgrade |
Operating Cash Flow | 54.54 | 17.2 | 7.5 | -2.14 | 74.39 | 44.79 | Upgrade |
Operating Cash Flow Growth | 144.13% | 129.34% | - | - | 66.09% | -49.14% | Upgrade |
Capital Expenditures | -12.8 | -5 | -5.12 | -17.45 | -12.05 | -19.01 | Upgrade |
Investment in Securities | 5.4 | 11.11 | 12.3 | 4.86 | -30.68 | -11.66 | Upgrade |
Other Investing Activities | -1.55 | -1.74 | -1.36 | 2.02 | 1.1 | - | Upgrade |
Investing Cash Flow | -8.95 | 4.38 | 5.82 | -10.57 | -41.63 | -30.68 | Upgrade |
Short-Term Debt Issued | - | - | 24.7 | - | - | - | Upgrade |
Long-Term Debt Issued | - | - | 210 | - | - | 547.72 | Upgrade |
Total Debt Issued | - | - | 234.7 | - | - | 547.72 | Upgrade |
Short-Term Debt Repaid | - | - | -24.7 | - | - | - | Upgrade |
Long-Term Debt Repaid | - | -0.39 | -198.89 | -6.67 | -6.74 | -271.7 | Upgrade |
Total Debt Repaid | -87.51 | -0.39 | -223.59 | -6.67 | -6.74 | -271.7 | Upgrade |
Net Debt Issued (Repaid) | -87.51 | -0.39 | 11.11 | -6.67 | -6.74 | 276.02 | Upgrade |
Issuance of Common Stock | 2.47 | 10.9 | 5.63 | 36.06 | 11.52 | 1.32 | Upgrade |
Repurchase of Common Stock | -2.21 | -9.87 | -4.89 | -49 | -45.77 | -9.37 | Upgrade |
Common Dividends Paid | - | - | - | - | - | -152.98 | Upgrade |
Other Financing Activities | - | -0.42 | -17.18 | - | -0.52 | 6.56 | Upgrade |
Financing Cash Flow | -87.25 | 0.23 | -5.33 | -19.61 | -41.51 | 121.55 | Upgrade |
Foreign Exchange Rate Adjustments | -0.19 | -1.47 | -1.68 | -1.27 | 1.11 | 0.4 | Upgrade |
Net Cash Flow | -41.85 | 20.33 | 6.31 | -33.58 | -7.64 | 136.07 | Upgrade |
Free Cash Flow | 41.74 | 12.2 | 2.37 | -19.58 | 62.34 | 25.78 | Upgrade |
Free Cash Flow Growth | 141.78% | 413.90% | - | - | 141.85% | -69.15% | Upgrade |
Free Cash Flow Margin | 16.97% | 3.68% | 0.81% | -5.97% | 16.10% | 7.79% | Upgrade |
Free Cash Flow Per Share | 0.97 | 0.29 | 0.06 | -0.50 | 1.59 | 0.71 | Upgrade |
Cash Interest Paid | 5.62 | 6.03 | 11.57 | 9.09 | 9.55 | 14.73 | Upgrade |
Cash Income Tax Paid | 6.87 | 10.18 | 11.19 | 12.27 | 6.18 | 2.18 | Upgrade |
Levered Free Cash Flow | 35.5 | 9.82 | 41.53 | 39.88 | 54.32 | 115.65 | Upgrade |
Unlevered Free Cash Flow | 42.76 | 17.66 | 50.76 | 48.88 | 63.07 | 129.86 | Upgrade |
Change in Working Capital | 50.57 | -41.63 | -1.74 | -65.32 | -61.29 | -28.92 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.